Solutions
Streamline the research and commercialization process by capitalizing on big-data analytics, target drug repurposing opportunities, and focus on the treatment of rare diseases.
Smart-ACTᵀᴹ
Accelerating the Commercialisation of Therapeutics
Using Computational Algorithms
& Big Data
Revolutionising Drug Repurposing
& Repositioning
Focusing on Orphan Diseases
& Unmet Medical Needs
Competitive Advantage
Reduce Development Time
by ~8 Years
Lower Cost by
over 90%
Higher Success Rate
Comparison
TRADITIONAL 3D
Problems
ACT 3D
Solutions
 Time
(years)
10-17 years¹
Drug Discovery:
3-10 years⁴
Preclinical stage:
1 year
Phase I:
Several Months⁵
Clinical stage:
5.4 years⁶
5-6.5 years
Drug Discovery:
1-1.5 years
Preclinical Development:
May not be needed
Phase I:
May not be needed
Phase II to market:
3.9 years⁶
Cost
US$2.6 billion²
US$33 million⁷
Probability
Low hit rate from discovery to commercialisation
– Expect 5 – 10 candidates to potentially enter clinical trials every year
Higher probability of success: 30% approval rate for repurposed drugs⁸
Potential of ACT
Orphan Diseases
7000
Pipeline
  • 5–10⁹ candidates potentially enter clinical trials each year
  • Expect 1ˢᵗ clinical asset in 2020 and cumulatively 4 clinical assets by 2023⁹
Potential Asset Pipeline Valuation
Projected mid-range value at US$42 billion⁹ by 2023
Clinical Development Costs
(Wet-lab, Phase 2, Phase 3)
  • US$33 million⁷ per cancer drug
  • US$120 million accumulated development costs by 2023
Return on Invested Capital
  • Per drug candidate: 4x to 5x (over 4 years)⁹
  • Perpetual pipeline: Systematic pipeline of clinical assets targeting orphan diseases and unmet medical needs!
Valuation of Smart-ActTM
Disclaimer: Value projections are illustrative only. All estimates and forward-looking projections are based on modeled assumptions, which we believe to be reasonable, and evidence based where applicable. However, such assumptions are subject to change based on newly emerging data and/or evidence, which could lead to changes in some or all projections presented in this leaflet. We disclaim any responsibility to update these projections in the event of such changes at any time in the future.
¹http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning; ²https://www.the-scientist.com/features/repurposing-existing-drugs-for-new-indications-32285; ³https://academic.oup.com/biostatistics/article/20/2/273/4817524; ⁴Estimated based on the overall development time of 10-17 years; ⁵https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm; ⁶Source: Drug Discov Today. 2012;17(13-14):660-4; ⁷Source: Key cost drivers of pharmaceutical clinical trials in the United States (PDF), pg 5 (121), Oncology; https://www.ncbi.nlm.nih.gov/pubmed/26908540; ⁸https://www.dcatvci.org/11-value-chain-insights/114-drug-repurposing-and-repositioning-making-new-out-of-old#; ⁹Smart Pharma internal estimates based on model assumptions. Details available upon request.